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The opportunistic Gram-negative bacterium Burkholderia cenocepacia causes lethal infections 
in cystic fibrosis patients. Multivalent mannoside derivatives were prepared as potential 
inhibitors of lectin BC2L-A, one of the virulence factors deployed by B. cenocepacia in the 
infection process. An (α1→2)-thio-linked mannobioside mimic bearing an azide functionalized 
aglycon was conjugated to different multivalent scaffolds such as propargylated calix[4]arenes, 
methyl gallate and pentaerythritol by azide-alkyne 1,3-dipolar cycloaddition. The interaction 
between the glycoclusters and the mannose binding BC2L-A lectin from B. cenocepacia was 
examined by isothermal microcalorimetry, surface plasmon resonance, inhibition of yeast 
agglutination and analytical ultracentrifugation. 
 
2016 Elsevier Ltd. All rights reserved.
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1. Introduction 
Burkholderia cenocepacia is a Gram-negative bacterium with 
the ability to form a biofilm. It is recognized as an opportunistic 
human pathogen causing lung infections in immunocompromised 
individuals, especially in cystic fibrosis patients, with significant 
mortality and morbidity.1 This bacterium produces three soluble 
lectins, named BC2L-A, BC2L-B and BC2L-C, which are 
homologues of the lectin PA-IIL from Pseudomonas aeruginosa, 
the most widespread pathogen attacking humans suffering from 
cystic fibrosis.2 These lectins are significant virulence factors of 
B. cenocepacia and are hypothesized to play an important role in 
host cell recognition and adhesion and in biofilm formation.3-5 
Therefore, they are considered novel therapeutic targets. 
The shortest, soluble Burkholderia lectin, BC2L-A, consisting of 
one PA-IIL like domain, associates as a dimer and displays a 
strict specificity for oligomannose-type N-glycans.2 Titration 
microcalorimetry measurements demonstrated that Me α-D-
mannoside as well as α-(1-2)-, α-(1-3)- and α-(1-6)-linked 
mannobiosides are high-affinity ligands for BC2L-A with 
micromolar dissociation constants.6 On the other hand, BC2L-A 
can bind directly to bacterial lipopolysaccharides (LPSs) on the 
outer membrane through L-glycero-D-manno-heptoses which are 
abundant in the LPSs of Burkholderia.3  It was thus proposed that 
this lectin can act as a cross-linker between bacterial cells and 
influence the social life of the bacteria (i.e. biofilm formation).3 
However, the strong affinity of BC2L-A for D-mannose, which 
can be found on epithelial cells, suggests that this lectin could be 
also directly involved in adhesion to the host cells. Consequently, 
competitive inhibitors which can strongly bind to the lectin can 
disrupt the colonization of the host by B. cenocepacia. 
With the goal of obtaining high affinity ligands of BC2L-A, 
which are potentially useful to block bacterial adhesion and are 
stable in vivo, we envisioned the synthesis of multivalent thio-
mannoside derivatives. Due to the cluster glycoside effect, 
multimeric carbohydrates generally exhibit an enhanced activity 
toward lectins compared to the corresponding monovalent ligand 
on a valence-corrected basis.7 Generally, replacement of the 
glycosidic oxygen with a sulfur atom improves the biological 
stability of the planned analogues against chemical and 
enzymatic hydrolysis. Furthermore, it has been reported that many 
lectins tolerate the thioglycosidic linkage, and some mannose- and 
galactose-specifis lectins show similar or even stronger affinity 
toward S-glycosides than the corresponding O-glycosides.8 
We recently reported a rapid and efficient synthesis of spacer-
armed (α1→2)-thio-linked mannobioside mimics via 
photoinduced hydrothiolation of the corresponding 2,3-
unsaturated glycoside.9 Having the azido-functionalized 
pseudomannobiosides 19b and 29b to hand, we envisioned their 
conjugation to multivalent scaffolds bearing terminal alkyne 
moieties by Cu(I)-catalyzed azide-alkyne cycloaddition 
reaction.10 To obtain glycoclusters displaying the mannobioside 
units in different spatial arrangements, various core compounds 
equipped with propargyl ether groups were used such as 
calix[4]arene derivatives 311 and 4,12 as well as perpropargylated 
methyl gallate 513 and pentaerythritol 614 (Figure 1).  
Here, we present the preparation of di- tri- and tetravalent 
thiomannobioside clusters and their interaction with the BC2L-A 
lectin isolated from Burkholderia cenocepacia. 
 
Figure 1. Spacer-linked (α1→2)-thio-linked pseudomannobiosides (1 and 2) 
and propargylated scaffolds (3-6) as starting materials for the targeted 
glycoclusters. 
 
2. Results and discussion 
2.1. Synthesis 
The azide-alkyne cycloaddition reactions were performed with 
both the protected and unprotected pseudomannobiosides 1 and 
2, respectively, using copper(I) iodide as the catalyst in the 
presence of triethylamine, under an argon atmosphere. We first 
coupled the peracetylated 1 with the tetra-O-propargylated 
scaffold 3 which could be prepared in one step from 
commercially available tert-butylcalix[4]arene. The reaction 
proceeded with moderate conversion within 24 h at room 
temperature to result in the protected tetravalent mannoside 
derivative 7 with an isolated yield of 11%. The cycloaddition 
took place in a similar manner using unprotected 2 as the azide 
reactant to give the desired mannocluster 8 in a 12% yield 
(Scheme 1). The limited efficacy of tetra-O-propargylated 
calix[4]arenes in a click reaction has already been described and 
is attributed to the high density of alkyne which promotes the 
side reaction, the homocoupling of scaffolded alkynes.11,15 
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Scheme 1. Synthesis of di- and tetravalent clusters with a calix[4]arene 
scaffold. Reagents and conditions: (a) Cu(I)I, Et3N, CH3CN, rt; (b) Cu(I)I, 
Et3N, DMF, rt; (c) NaOMe, MeOH, rt. 
 
Conjugation of the protected sugar 2 to the calix[4]arene 
derivative 4 bearing only two propargyl moieties occurred with 
an excellent 88% yield, and subsequent Zemplén deacetylation of 
the resulting 9 yielded the bivalent thiomannobioside 10 in a 73% 
yield.  
The synthesis of the pseudomannobioside-appended methyl 
gallate conjugate 12 and pentaerythritol conjugate 14 occurred 
with good yields, using either the protected or the unprotected 
sugar derivatives, as shown in Scheme 2. Interestingly, slightly 
higher yields could be achieved if the unprotected 
pseudomannobioside 2 was used in the click reaction, despite the 
difficult separation of the polar products.  
 
 
 
 
 
Scheme 2. Synthesis of methyl gallate- and pentaerythritol-based clusters. 
Reagents and conditions: (a) Cu(I)I, Et3N, CH3CN, rt; (b)  Cu(I)I, Et3N, 
DMF, rt; (c) NaOMe, MeOH, rt. 
  
 
2.2. Binding of BC2L-A to multivalent thiomannosides 
Investigations of the interaction of the multivalent 
thiomannobioside derivatives with mannose-binding lectin 
BC2L-A were carried out using a simple microscopy method for 
the inhibition of agglutination, isothermal titration calorimetry 
(ITC), surface plasmon resonance (SPR) and analytical 
ultracentrifugation (AUC). These methods can provide 
information about the binding affinity, inhibition potency and 
effect of cross-linking. 
The activity of BC2L-A was verified via its interaction with 
methyl α-D-mannopyranoside, measured by ITC. Results 
comparable with those previously published were obtained.2  
We attempted to incorporate all multivalent mannoside 
derivatives in the biological investigations. Although the utility 
of calixarene-based glycoconjugates in sugar-lectin binding 
assays has already been demonstrated,16 the amphiphilic 
calix[4]arene clusters 8 and 10, unfortunately, could not be used 
in this study because of their low solubility in water and 
water−DMSO mixture. Therefore, we focused on the interaction 
of compounds 12 and 14 with BC2L-A. 
As for 12 and 14, the interactions with BC2L-A observed by 
ITC resulted in exothermic peaks, which is typical for 
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interactions of BC2L-A with carbohydrates.2,3 However, the 
peaks were significantly (10x) higher than typical interactions of 
BC2L-A, and saturation was not reached. Therefore reliable 
evaluation of the interactions was not possible. These problems 
probably result from the interaction itself and are not caused 
simply by the behaviour of 12 and 14, because they persisted 
even after the blank measurement (injection of 12 or 14 to the 
buffer) subtraction. A possible explanation could be cross-linking 
of BC2L-A molecules with multivalent compounds and 
subsequent aggregation. 
The potential inhibitory activity of 12 and 14 toward BC2L-A 
was tested via a biosensor with SPR detection. Both compounds 
were used as inhibitors of BC2L-A binding to the immobilized α-
D-mannopyranoside in the verified set-up, with methyl α-D-
mannopyranoside as a control.2,4 Both 12 and 14 were able to 
inhibit the binding of BC2L-A to the glycosylated surface with 
the inhibition potency of 12 being only slightly higher (1.3) than 
that of methyl α-D-mannopyranoside. The inhibition potency of 
14 was more than double that of methyl α-D-mannopyranoside 
(2.17, see Table 1).  
Table 1. IC50 values obtained by SPR for the inhibition of binding of BC2L-
A to immobilized α-D-mannopyranoside. 
 
Inhibitor IC50(µM) Potency 
αMeMan 42.45 1 
Compound 12 32.65 1.3 
Compound 14 19.53 2.17 
 
Figure 2. Inhibitory effects of 12 and 14 on BC2L-A binding to immobilized 
α-D-mannopyranoside with methyl α-D-mannopyranoside used as a control 
and standard  
 
 
 
Non-standard behaviour was again observed. The binding 
responses of BC2L-A mixed with the two lowest concentrations 
(4.88  µM and 9.65 µM) of 12 and 14 were actually higher than 
the response of mere BC2L-A, resulting in negative inhibition 
(i.e. promotion of the interaction, Figure 2). Again, this 
behaviour could be caused by cross-linking of the BC2L-A 
molecules. The SPR detects the mass bound to the surface. 
Therefore, the binding of cross-linked molecules of BC2L-A via 
one single active binding site could actually generate the same 
response as the binding of several molecules of active BC2L-A 
and cause falsely increased responses.  
Therefore, the inhibitory activity of 12 and 14 was also tested 
using a yeast agglutination inhibition assay. BC2L-A as a 
mannose-specific lectin can agglutinate yeasts. Both 12 and 14 
were able to inhibit this agglutination, with results corresponding 
to that obtained via SPR (Table 2). 
Table 2. The values obtained for the inhibition of yeasts agglutination caused 
by BC2L-A. 
Inhibitor 
The lowest  
concentration 
able to inhibit 
agglutination  
Potency Note 
αMeMan 12.5 mM 1 Standard 
D-Man 25 mM 0.5  
D-Gal Not detected  Negative 
control 
12 12.5 mM 1  
14 6.25 mM 2  
 
The inhibitory effect of 12 was the same as for methyl α-D-
mannopyranoside, whereas 14 was twice as effective as  methyl 
α-D-mannopyranoside (see Table 3). Also, the yeast agglutination 
inhibition assay with detection with an optical microscope proved 
to be a simple and inexpensive method for testing newly 
synthesized compounds. Using this assay, even the differences 
between the inhibition potencies of D-mannose and methyl α-D-
mannopyranoside could be observed, and the results were in 
agreement with the previously published data (see Table 2).2 
Table 3. Influence of 12 and 14 on yeast agglutination caused by lectin 
BC2L-A. Several pictures were taken for each concentration of inhibitor. 
Compounds 12 and 14 were able to inhibit agglutination at concentrations 
above 12.5 mM and 6.25 mM, respectively. 
 
 
25 mM 
12  
 
12.5 mM 
12 
12.5 mM 
14 
6.25 mM 
12 
6.25 mM 
14 
3.125 mM 
12 
3.125 mM 
14 
1.562 mM 
12 
1.562 mM 
14 
0.781 mM 
12 
0.781 mM 
14 
 
 
0.391 mM 
14 
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The expected cross-linking of BC2L-A via compounds 12 and 14 
was verified using analytical ultracentrifugation. BC2L-A itself 
sediments at 2.5 S and forms a dimer with a globular shape (with 
an estimated molecular weight of 27.5 kDa and frictional ratio of 
1.28). Mixing BC2L-A with compound 14 resulted in the 
formation of a wide range of small oligomers/aggregates (Figure 
3). Since the reaction scheme of the system (divalent lectin, 
tetravalent ligand) can be quite complicated, and we cannot 
exclude the possibility that the interaction is governed by fast 
reaction kinetics (relative to the time-scale of sedimentation) 
where the positions of the peaks shift in a concentration-
dependent manner, no attempts were made to identify the nature 
of the peaks observed in the molar ratios 1:1 and 1:2. The ratio 
1:10 resulted mainly in the dimeric form of BC2L-A, suggesting 
that all binding sites of the protein are saturated and cross-linking 
is not possible. No precipitation visible to the naked eye was 
observed. The addition of compound 12 to BC2L-A also caused 
the formation of higher oligomers (Figure 3). 
 Figure 3. Continuous c(s) distributions for BC2L-A with 14 (left) and 12 
(right). The figures were created in the program GUSSI.17 
 
  
Again the reaction scheme seems to be quite complex. Slight 
precipitation was visible in samples with a BC2L-A:compound 
12 ratio of 1:2 and 1:10. High concentrations of compound 12 in 
these samples resulted in very high absorbance (due to the 
aromatic core) and the data from the 1:2 and 1:10 ratios could not 
be evaluated. Nevertheless, analytical ultracentrifugation gave 
clear evidence of the cross-linking of BC2L-A with compound 
12.  
3. Conclusion 
In conclusion, we have demonstrated a simple and highly 
efficient approach to produce various glycoclusters with terminal 
1,2-thio-linked pseudomannobiosides. The azide-functionalized 
pseudodisaccharides, both in their protected and unprotected 
forms, could be conjugated to the propargyl-containing scaffolds 
with similar efficacy. Investigations of the interactions of the 
derivatives with mannose-specific lectin BC2L-A were carried 
out and resulted in confirming that compounds 12 and 14 are able 
to inhibit the binding activity of the lectin, although the 
inhibitory effect was not as high as expected. Compounds 12 and 
14 are probably unable to chelate both binding sites of the BC2L-
A dimer and achieve increased affinity. The compounds instead 
cross-link and aggregate BC2L-A molecules. This behaviour has 
been observed previously in interactions of BC2L-A with 
multivalent inhibitors.18 Those mannosylated inhibitors were too 
short to connect the two binding sites of BC2L-A that are 40 Å 
apart. In the present study, compounds 12 and 14 possess 
sufficient span but are still unable to achieve significantly 
increased inhibitory effect. Therefore, this phenomenon is 
probably not a simple problem of the length but involves possibly 
also steric hindrances and conformations of compounds 12 and 
14 in the solution. However, cross-linking of surface lectins can 
cause an agglutination of bacteria presenting these lectins, as was 
observed for the lectin PA-IIL from Pseudomonas aeruginosa.19 
This process resulted in interference with biofilm production and 
bacteria-host cell interactions. Therefore, compounds 12 and 14 
are suitable candidates to investigate in terms of their ability to 
interfere with Burkholderia cenocepacia functions at the cell 
level. Also, a study is planned of the interaction of these 
mannoclusters with BC2L-C,4 another lectin of B. cenocepacia. 
 
4. Experimental 
4.1. General methods 
Optical rotations were measured at room temperature with a 
Perkin-Elmer 241 automatic polarimeter. TLC analysis was 
performed on Kieselgel 60 F254 (Merck) silica gel plates with 
visualization by immersing in a sulfuric-acid solution (5% in 
EtOH) followed by heating. Column chromatography was 
performed on silica gel 60 (Merck 0.063–0.200 mm), flash 
column chromatography was performed on silica gel 60 (Merck 
0.040–0.063 mm). Gel filtration was performed on Sephadex G-
25, using methanol as the eluent. Organic solutions were dried 
over MgSO4 and concentrated under vacuum. The 1H (400 and 
500 MHz) and 13C NMR (100.28, 125.76 MHz) spectra were 
recorded with Bruker DRX-360, Bruker DRX-400 and Bruker 
Avance II 500 spectrometers. Chemical shifts are referenced to 
Me4Si or DSS (0.00 ppm for 1H) and to solvent signals (CDCl3: 
77.00 ppm, CD3OD: 49.15 ppm, DMSO-d6: 39.51 ppm for 13C). 
MS (MALDI-TOF) analysis was carried out in positive reflectron 
mode with a BIFLEX III mass spectrometer (Bruker, Germany) 
with delayed-ion extraction. The matrix solution was a saturated 
solution of 2,4,6-trihydroxy-acetophenone (THAP) in MeCN. 
The recombinant protein BC2L-A was cloned using the 
previously described procedure and purified by affinity 
chromatography2. Isothermal titration calorimetry (ITC) 
experiments were measured using Auto-iTC200 (Malvern 
Instruments). Surface plasmon resonance (SPR) experiments 
were performed using a BIAcore 3000 (GE Healthcare) at 25 °C. 
Agglutination experiments were carried out using commercially 
available baker’s yeast (Uniferm) and agglutination/inhibition of 
agglutination was determined with an optical microscope, a 
Levenhuk D2L NG Digital Microscope (Levenhuk). Analytical 
ultracentrifugation experiments were performed using a 
ProteomeLab XL-I analytical ultracentrifuge (Beckman Coulter) 
equipped with an An-60 Ti rotor. 
4.2. Protein production and purification 
Protein was produced in Escherichia coli BL21(DE3) as 
previously described.2 Transformed cells were cultured in LB 
broth medium containing ampicillin (100 µg.ml-1) at 37 °C. 
When the culture reached an OD600 of 0.5, cells were induced by 
isopropyl 1-thio-β-D-galactopyranoside (IPTG) added to a final 
concentration of 0.5 mM. Cells were incubated at 27 °C for 4 
hours, harvested by centrifugation and resuspended in 
equilibrating buffer (20 mM Tris/HCl, 100 mM NaCl, pH 7.4). 
Cells were then disintegrated by sonication and the cytosolic 
fraction containing soluble BC2L-A was separated by 
centrifugation. BC2L-A was purified by affinity chromatography 
on a D-mannose-agarose column and eluted with 20 mM 
Tris/HCl, 150 mM NaCl, 10 mM EDTA, pH 7.4. Purified protein 
was dialysed (against 10 mM Tris/HCl, 50 mM NaCl, 1 mM 
CaCl2 for 2 days, then against 50 mM NH4HCO3 for 2 days), 
freeze-dried and stored at -20 °C. 
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4.3. Isothermal titration calorimetry 
Freeze-dried BC2L-A was dissolved in 0.1 M Tris/HCl, 500 µM 
CaCl2, pH 7.5, and equilibrated at room temperature for 1 h 
before ITC measurement. All experiments were performed in an 
Auto-iTC200 calorimeter (Malvern Instruments) at 25°C. 
Compounds 12 and 14 were used at a concentration of 2 mM. 
Aliquots of 2 µl were added automatically to the 0.2 mM BC2L-
A in the calorimeter cell. Blank experiments (injections of 12 and 
14 into the buffer) were performed, and heat responses were 
subtracted. Control experiments performed by injections of the 
buffer to the protein solution yielded insignificant heats of 
dilution. Integrated heat effects were analysed using Microcal 
Origin 7 software (Malvern Instruments). The activity of freeze-
dried BC2L-A was tested via interaction with methyl α-D-
mannopyranoside. 
4.4. Surface plasmon resonance 
Surface plasmon resonance (SPR) experiments were performed 
on a BIAcore 3000 instrument (GE Healthcare) at 25 °C, using 
10 mM HEPES, 150 mM NaCl, 0.005 % TWEEN 20, pH 7.4 as a 
running buffer. Two different carbohydrates were immobilized 
onto a CM5 sensor chip (GE Healthcare) covered with a 
carboxymethylated dextran matrix: α-D-galactopyranoside and α-
D-mannopyranoside. The sensor chip surface was first coated 
with streptavidin using a standard amine coupling method. The 
carboxymethytaled surface was activated with an N-
hydroxysuccinimide/N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride solution (NHS/EDC, GE 
Healthcare) and streptavidin diluted in 10 mM sodium acetate, 
pH 5.0 to a concentration of 100 µg.ml-1 was injected onto the 
CM5 chip. Unreacted groups were blocked with 1 M 
ethanolamine-HCl, pH 8.5. The volume of all solutions was 50 µl 
for one channel at a flow rate of 5 µl/min. Saccharides bound to 
the biotinylated polyacrylamide (biotin-PAA-monosaccharides, 
Lectinity) were then used for the immobilization. Each biotin-
PAA-monosaccharide was diluted in the running buffer to a 
concentration of 200 µg.ml-1, and 50 µl of this mixture was 
injected onto one particular channel. The flow rate was 5 µl/min. 
Protein BC2L-A at a concentration of 500 µg.ml-1 was mixed 
with 10x concentrated inhibitors in a 9:1 ratio. 30 µl of this 
mixture was injected onto the CM5 chip with immobilized 
carbohydrates at a flow rate of 5 µl/min. The sensor chip was 
washed with 100 mM EDTA. IC50 (concentration of inhibitor 
resulting in 50% inhibition of binding) was determined. As IC50 
is not a constant and depends on the experimental set-up, a 
parameter called potency was used for characterization. The 
potency of a certain inhibitor is the ratio of IC50 of a chosen 
standard inhibitor (in this case methyl α-D-mannopyranoside) and 
the inhibitor in question. As BC2L-A does not bind to α-D-
galactopyranoside, the corresponding channel was used as a 
blank.  
4.5. Agglutination inhibition assay 
Freeze-dried lectin BC2L-A, carbohydrate inhibitors and yeast 
cells (Uniferm) were dissolved in the working buffer (20 mM 
Tris/HCl, 150 mM NaCl, 5 mM CaCl2, pH 7.5). The lectin (2.5 
mg.ml-1) was mixed with serially diluted carbohydrate inhibitors 
in a 5 µl:5 µl ratio. The final (working) concentration of the 
lectin was therefore 1.25 mg.ml-1 and the final concentration of 
carbohydrate inhibitors varied from 100 mM to 0.391 mM. 10 µl 
of 5% yeast was then added, the mixture was thoroughly mixed 
and incubated for 10 minutes at room temperature. After 
incubation, the mixture was again mixed, transferred to a 
microscope slide and examined. The examination was conducted 
using the Levenhuk D2L NG Digital Microscope (Levenhuk). 
Images were obtained with a Levenhuk D2L digital camera 
(Levenhuk) using the software ToupView for Windows 
(Levenhuk). The positive (experiment without inhibitor) and 
negative control (experiment without lectin) were prepared and 
processed in the same way using the appropriate volume of 
dissolving buffer instead of the omitted components. The lowest 
concentration of inhibitor able to inhibit agglutination was 
determined and compared with the standard (methyl α-D-
mannopyranoside). As BC2L-A cannot recognize D-galactose, 
this carbohydrate was used as a negative control.    
4.6. Analytical ultracentrifugation 
Analytical ultracentrifugation experiments were performed using 
a ProteomeLab XL-I analytical ultracentrifuge (Beckman 
Coulter) equipped with an An-60 Ti rotor. BC2L-A and 
compounds 12 and 14 were diluted with the experimental buffer 
(20 mM Tris/HCl, 150 mM NaCl, 0.5 mM CaCl2, pH 7.5) and 
several mixtures with different lectin to ligand ratios were 
prepared. In all cases, the concentration of BC2L-A was 72 µM 
and lectin:ligand molar ratios of 1:0.1, 1:0.5, 1:1, 1:2 and 1:10 
were tested. BC2L-A without the ligand added was also 
measured. .Sedimentation velocity experiments were conducted 
in standard double-sector centerpiece cells loaded with 425 ul of 
sample and 425 ul of reference solution (20 mM Tris/HCl, 150 
mM NaCl, 0.5 mM CaCl2, pH 7.5). Data were collected using 
absorbance optics at 20° C at a rotor speed of 48,000 rpm. Scans 
were collected at 280 nm at 5-min intervals and 0.003 cm spatial 
resolution in continuous scan mode. The partial specific volume 
of protein and the solvent density and viscosity were calculated 
from the amino acid sequence and buffer composition, 
respectively, using the software Sednterp 
(http://bitcwiki.sr.unh.edu). The data were analyzed with the 
continuous c(s) distribution model implemented in the program 
Sedfit 14.6.20 For the regularization procedure, a confidence level 
of 0.95 was used. High-quality plots of continuous distributions 
were created in GUSSI 1.10.17 
4.7. Synthesis 
4.7.1. General method A for azide-alkyne click reaction 
(5 mL) Et3N (1 equiv. /alkyne) and Cu(I)I (0.1 equiv. /alkyne) 
were added to a stirred solution of alkyne (0.2 mmol) and azide 
(1.25 equiv./alkyne) in DMF or CH3CN under an argon 
atmosphere and stirred overnight at room temperature. The 
reaction mixture was evaporated, and the crude product was 
purified by flash column chromatography to give the desired 
compound. 
4.7.1. General method B for Zemplén-deacetylation 
The catalytic amount of NaOMe (pH ~ 9) was added to a stirred 
solution of ester (0.2 mmol) in dry MeOH (5 mL) and stirred 
overnight at room temperature. The reaction mixture was 
neutralized with Amberlite IR-120 ion-exchange resin, filtered 
and evaporated, then the crude product was purified by flash 
column chromatography and gel filtration to give the desired 
compound. 
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4.7.2. Compound 7 
Azide compound 1 (152 mg, 0.2 mmol) and alkyne 3 (30 mg, 
0.04 mmol) were reacted in CH3CN according to the general 
method A. The crude product was purified by flash column 
chromatography (95:5 CH2Cl2:MeOH) to give compound 7 (16 
mg, 11%) as a colourless syrup. [α]24D +88.30 (c 0.49, CHCl3); Rf 
0.30 (95:5 CH2Cl2: MeOH); 1H NMR (CDCl3, 500.76 MHz): δ 
(ppm) 7.75 (s, 4H, 4x H-Tr), 6.65 (s, 8H, 8x H-Ar), 5.38- 5.35 
(overlapping signals, 8H, 4x H-1’, 4x H-2’), 5.30 (t, 4H, 4x H-4’, J= 
9.9 Hz), 5.24 (dd, 4H, 4x H-3’, J1= 3.1 Hz, J2= 9.9 Hz), 5.03 (m, 4H, 
4x H-4), 4.85 (s, 4H, 4x H-1), 4.97 (s, 8H, 4x OCH2Ar), 4.67 (m, 
8H, 4x NCH2), 4.38 (m, 4H, 4x H-5’), 4.28 (dd, 4H, J1= 5.3 Hz, J2= 
12.3 Hz, 4x H-6’a), 4.20 (dd, 4H, J1= 2.4 Hz, J2= 12.3 Hz, 4x H-6a), 
4.15 (dd, 4H, J1= 5.3 Hz, J2= 12.3 Hz, 4x H-6b), 4.11 (dd, 4H, J1= 
5.3 Hz, J2= 12.3 Hz, 4x H-6’b), 3.97 (m, 4H, 4x H-5), 3.93 (m, 4H, 
2x ArCH2aAr), 3.80- 3.50 (overlapping signals, 56H, OCH2), 3.24 
(m, 4H, 4x H-2), 2.87 (m, 4H, 2x ArCH2bAr), 2.23 (m, 8H, 4x H-3), 
2.17, 2.11, 2.09, 2.06, 2.04, 1.99, (s, 72H, 24x COCH3),1.07 (s, 36H, 
C(CH3)3). 13C NMR (CDCl3, 125.76 MHz): δ (ppm) 170.8, 170.5, 
169.9, 169.8, 169.7 (CO), 152.5 (Cq-Ar), 143.9 (Cq-Tr), 133.9 (Cq-
Ar), 133.7 (Cq-Ar), 129.7 (Cq-Ar), 125.2 (CH-Tr), 125.1 (CH-Ar), 
98.8 (C-1), 82.4 (C-1’), 70.9, 70.5, 70.4, 70.1, 69.3, 68.8, 68.7, 66.2, 
64.7 (skeleton carbons and OCH2), 62.9 (C-6), 62.3 (C-6’), 50.5 
(NCH2), 44.9 (C-2), 33.9 (C(CH3)3), 31.7 (ArCH2Ar), 31.3 
(C(CH3)3), 29.1 (C-3), 21.0, 20.9, 20.7, 20.6 (COCH3). MALDI-
TOF (positive ion): m/z calcd for C184H260N12NaO76S4: 4004.56 
[M+Na]+ Found: 4004.60. 
4.7.3. Compound 8  
Azide compound 2 (106 mg, 0.2 mmol) and alkyne 3 (30 mg, 
0.04 mmol) were reacted in DMF according to the general 
method. The crude product was purified by flash column 
chromatography (8:5:1 CH2Cl2:MeOH:H2O) to give compound  8 
(13 mg, 12%) as a colourless syrup. [α]24D +88.30 (c 0.49, 
MeOH); Rf  0.56 (16:10:3 CH2Cl2:MeOH:water) 1H NMR 
(DMSO, 500.76 MHz): δ (ppm) 8.04 (s, 4H, 4x H-Tr), 6.70 (s, 8H, 
8x H-Ar), 5.20 (s, 4H, 4x H-1’), 4.76 (s, 4H, 4x H-1), 4.56 (m, 8H, 
4x NCH2), 4.15- 3.15 (overlapping signals, 136H, skeleton 
hydrogens, ArCH2Ar and OCH2), 3.09 (s, 4H, 4x H-2), 2.05 (m, 8H, 
4x H-3), 1.07 (s, 36 H, C(CH3)3), 13C NMR (DMSO, 125.76 MHz): δ 
(ppm) 143.7 (Cqvat-Tr), 133.6 (Cq-Ar), 124.5 (CH-Tr), 123.7 (CH-
Ar), 98.4 (C-1), 86.1 (C-1’), 74.6, 74.4, 71.7, 71.6, 69.7, 69.6, 69.5, 
69.4, 68.8, 67.3, 65.7, 61.9 (skeleton carbons and OCH2), 61.1 (C-6), 
60.7 (C-6’), 49.2 (NCH2), 45.4 (C-2), 33.5 (C-3 and C(CH3)3), 31.1 
C(CH3)3, 29.7 (ArCH2Ar). MALDI-TOF (positive ion): m/z calcd 
for C136H212N12NaO52S4: 2996.31 [M+Na]+ Found: 2996.30  
4.7.4. Compound 9 
Azide compound 1 (168 mg, 0.2 mmol) and alkyne 4 (60 mg, 
0.08 mmol) were reacted in CH3CN according to the general 
method A. The crude product was purified by flash 
chromatography (95:5 CH2Cl2: MeOH) to give compound 9 (164 
mg, 88%) as a colourless syrup. [α]24D +72.07 (c 0.37, CHCl3); Rf 
0.27 (95:5 CH2Cl2: MeOH); 1H NMR (CDCl3, 400.28 MHz): δ 
(ppm) 8.13 (s, 2H, 2x H-Tr), 7.03 (s, 4H, 4x H-Ar), 6.84 (s, 4H, 4x 
H-Ar), 5.38- 5.37 (overlapping signals, 4H, 2x H-1’, 2x H-2’), 5.30 
(t, 2H, 2x H-4’ J= 9.9 Hz), 5.23 (dd, 2H, 2x H-3’, J1= 3.1 Hz, J2= 9.9 
Hz), 5.17 (s, 6H, 3x OCH2Ar), 5.03 (m, 2H, 2x H-4), 4.84 (s, 2H, 2x 
H-1), 4.57 (m, 4H, 2x NCH2), 4.37 (m, 2H, 2x H-5’), 4.30 (dd, 2H, 
2x H-6’a), 4.24 (d, 4H, ArCH2aAr), 4.18- 4.05 (overlapping signals, 
6H, 2x H-6, 2x H-6’b), 3.96 (m, 2H, 2x H-5), 3.86 (m, 6H, 3x 
OCH2), 3.79 (m, 2H, OCH2), 3.70- 3.46 (overlapping signals, 20H, 
OCH2), 3.29 (d, 4H, ArCH2bAr, J= 12.8 Hz), 3.23 (m, 2H, 2x H-2), 
2.20 (m, 4H, 2x H-3), 2.17, 2.10, 2.09, 2.05, 2.04, 1.99 (s, 36H, 12 x 
COCH3), 1.27 (s, 18H, C(CH3)3), 0.98 (s, 18H, C(CH3)3), 13C NMR 
(CDCl3, 100.28 MHz): δ (ppm) 170.8, 170.5, 169.7, 169.9 (CO), 
150.3, 149.5 (Cq-Ar), 147.3, (Cq-Tr), 143.9, 141.7 (Cq-Ar), 132.5 
(Cq-Ar), 127.6 (Cq-Ar), 125.6 (CH-Ar), 125.0 (CH-Ar), 124.5 (CH-
Tr), 98.7 (C-1), 82.3 (C-1’), 70.8, 70.4, 70.3, 69.9, 69.3, 69.2, 68.7, 
66.8, 66.1, 64.6 (skeleton carbons and OCH2), 62.8 (C-6’), 62.2 (C-
6), 50.1 (NCH2), 44.6 (C-2), 33.9 (C(CH3)3), 33.7 (C(CH3)3), (31.7 
(ArCH2Ar), 31.6 (C(CH3)3), 30.9 (C(CH3)3), 29.1 (C-3), 20.9, 20.8, 
20.6, 20.5 (COCH3). MALDI-TOF (positive ion): m/z calcd for 
C114H158N6NaO40S2: 2337.99 [M+Na]+ Found: 2337.99  
4.7.5. Compound 10 
Compound 9 (164 mg, 0.07 mmol) was deprotected according to 
general method B to result in compound 10 (47 mg, 73%). [α]24D 
+117.0 (c 0.05, MeOH); Rf 0.61 (8:5:1 CH2Cl2: MeOH:water); 1H 
NMR (DMSO, 500.76 MHz): δ (ppm): 8.24 (s, 2H, H-Tr),7.40- 6.90 
(s, 8H, H-Ar), 5.19 (s, 2H, 2x H-1’), 5.15 (s, 2H, OCH2), 4.75 (s, 2H, 
2x H-1), 4.80 (m, 4H, NCH2), 4.75- 3.15 (overlapping signals, 72H, 
skeleton hydrogens, ArCH2Ar and OCH2), 3.09 (m, 2H, 2x H-2), 
2.05, 2.03 (m, 4H, 2x H-3), 1.15, 1.09 (s, 36 H, 4 x C(CH3)3), 13C 
NMR (DMSO, 125.76 MHz): δ (ppm) 151.9, 142.6 (Cq-Tr), 134.1, 
133.1, 129.8, 128.9, 127.5 (Cq-Ar), 125.5 (CH-Ar), 125.1 (CH-Tr), 
98.4 (C-1), 86.1 (C-1’), 74.6, 74.4, 71.7, 71.6, 69.7, 69.6, 68.9, 67.3, 
65.7, 61.9 (skeleton carbons and OCH2), 61.06 (C-6), 61.04 (C-6’), 
49.5 (NCH2), 45.5 (C-2), 33.5 (2C, C-3 and C(CH3)3), 32.5 
(ArCH2Ar), 31.4 (C(CH3)3), 31.1 (C(CH3)3). MALDI-TOF 
(positive ion): m/z calcd for C94H134N6NaO28S2 [M+Na]: 1833.86. 
Found: 1833.87. 
4.7.6. Compound 11 
Azide compound 1 (256 mg, 0.3 mmol) and alkyne 5 (25 mg, 
0.08 mmol) were reacted in CH3CN according to the general 
method A. The crude product was purified by flash 
chromatography (95:5 CH2Cl2: MeOH) to give compound 11 
(110 mg, 54%) as a colourless syrup. [α]24D +3.32 (c 0.09, 
CHCl3); Rf 0.26 (95:5 CH2Cl2: MeOH); 1H NMR (CDCl3, 500.76 
MHz): δ (ppm) 7.94 (s, 3H, 3x H-Tr), 7.46 (s, 2H, 2x H-Ar), 5.38- 
5.35 (overlapping signals, 6H, 3x H-1’, 3x H-2’), 5.31 (t, 3H, 3x H-
4’, J= 9.9 Hz), 5.28- 5.20 (overlapping signals, 5H, 3x H-3’, OCH2), 
5.04 (m, 3H, 3x H-4), 4.85 (s, 3H, 3x H-1), 4.58 (m, 6H, 3x NCH2), 
4.38 (m, 3H, 3x H-5’), 4.28 (dd, 3H, J1= 5.3 Hz, J2= 12.3 Hz, 3x H-
6’a), 4.19 (dd, 3H, J1= 2.4 Hz, J2= 12.3 Hz, 3x H-6a), 4.15 (dd, 3H, 
J1= 5.3 Hz, J2= 12.3 Hz, 3x H-6b), 4.10 (dd, 3H, J1= 5.3 Hz, J2= 12.3 
Hz, 3x H-6’b), 3.97 (m, 3H, 3x H-5), 3.95- 3.50 (overlapping 
signals, 5H, OCH2, OCH3), 3.86 (m, 2H, OCH2), 3.80 (m, 2H, 
OCH2), 3.70- 3.50 (overlapping signals, 40H, OCH2), 3.24 (m, 3H, 
3x H-2), 2.23 (m, 6H, 3x H-3), 2.17, 2.11, 2.09, 2.06, 2.04, 1.99, (s, 
54H, 18x COCH3). 13C NMR (CDCl3, 125.76 MHz): δ (ppm) 170.5, 
169.8, 169.9, 169.8, 169.7, 169.6 (CO), 152.0 (Cq-Ar), 144.0 (Cq-
Ar), 143.7 (Cq-Tr), 141.8 (Cq-Ar), 124.9 (CH-Tr), 124.3 (CH-Ar), 
109.1 (CH-Ar), 98.8 (C-1), 82.4 (C-1’), 70.9, 70.5, 70.4, 70.1, 69.4, 
69.3, 69.1, 68.7, 66.8, 66.2, 64.8 (skeleton carbons and OCH2), 62.8 
(C-6), 62.3 (C-6’), 52.3 (OCH3), 50.0 (NCH2), 44.7 (C-2), 29.2 (C-
3), 21.0, 20.9, 20.7, 20.6 (COCH3). MALDI-TOF (positive ion): 
m/z calcd for C113H161N9NaO59S3: 2706.86 [M+Na]+ Found: 
2706.89. 
4.7.7. Compound 12  
Azide compound 2 (356 mg, 0.64 mmol) and alkyne 5 (50 mg, 
0.17 mmol) were reacted in DMF according to the general 
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method A. The crude product was purified by flash 
chromatography (8:5:1 CH2Cl2: MeOH:water) to give compound 
12 (240 mg, 63%) as a colourless syrup.  
Compound 12 was also prepared by deacetylation of compound 
11 (110 mg, 0.04 mmol) according to general method B to result 
in compound 12 (55 mg, 70%). [α]24D +86.43 (c 0.17, MeOH); Rf 
0.32 (8:5:1 CH2Cl2: MeOH:water); 1H NMR (DMSO, 500.76 
MHz): δ (ppm) 8.18 (s, 3H, H-Tr), 7.44 (s, 2H, H-Ar), 5.20- 5.19 
(overlapping signals, 9H, 3x H-1’, 3x OCH2), 4.76 (s, 3H, 3x H-1), 
4.56 (m, 6H, 3x NCH2,), 3.85 (s, 3H, OCH3), 3.84 (m, 6H, 3x 
OCH2), 3.81- 3. 46 (overlapping signals, 84H, skeleton hydrogens 
and OCH2,), 3.40 (m, 3H, 3x H-4), 3.10 (m, 3H, 3x H-2), 1.99, 1.93 
(m, 6H, 3x H-3), 13C NMR (DMSO, 125.76 MHz): δ (ppm) 165.8 
(CO), 151.8 (Cq-Ar), 143.0 (Cq-Tr), 142.3 (Cq-Ar), 141.1 (Cq-Ar), 
124.8 (CH-Tr), 108.7 (CH-Ar), 98.3 (C-1), 86.1 (C-1’), 74.6, 74.4, 
71.6, 71.5, 69.8, 69.6, 69.5 , 68.7, 67.3, 65.5 , 62.3, 61.9 (skeleton 
carbons and OCH2), 61.1 (C-6’), 61.0 (C-6), 52.3 (OCH3), 49.4 
(NCH2), 45.4 (C-2), 33.5 (C-3). MALDI-TOF (positive ion): m/z 
calcd for C77H125N9NaO41S3 [M+Na]+ 1950.70. Found: 1950.75. 
4.7.9. Compound 13 
Azide compound 1 (204 mg, 0.25 mmol) and alkyne 6 (15 mg, 
0.05 mmol) were reacted in CH3CN according to the general 
method A. The crude product was purified by flash 
chromatography (98:2 CH2Cl2: MeOH) to give compound  13 (91 
mg, 50%) as a colourless syrup. [α]24D +73.85 (c 0.08, CHCl3); Rf 
0.31 (95:5 CH2Cl2: MeOH); 1H NMR (CDCl3, 500.76 MHz): δ 
(ppm) 7.72 (s, 4H, 4x H-Tr), 5.38- 5.37 (overlapping signals, 8H, 4x 
H-1’, 4x H-2’), 5.30 (t, 4H, 4x H-4’, J= 9.9 Hz), 5.23 (dd, 4H, 4x H-
3’, J1= 3.1 Hz, J2= 9.9 Hz), 5.03 (m, 4H, 4x H-4), 4.85 (s, 4H, 4x H-
1), 4.55 (t, 8H, 4x NCH2), 4.53 (m, 8H, 4x OCH2,) 4.38 (m, 4H, 4x 
H-5’), 4.28 (dd, 4H, J1= 5.3 Hz, J2= 12.3 Hz, 4x H-6’a), 4.19 (dd,, 
4H, J1= 2.4 Hz, J2= 12.3 Hz, 4x H-6a), 4.14 (dd, 4H, J1= 5.3 Hz, J2= 
12.3 Hz, 4x H-6b), 4.11 (dd, 4H, J1= 5.3 Hz, J2= 12.3 Hz, 4x H-6’b), 
3.97 (m, 4H, 4x H-5), 3.89 (m, 8H, 4x OCH2,), 3.80 (m, 4H, 2x 
OCH2), 3.85- 3.56 (overlapping signals, 56H, 28x OCH2), 3.48 (s, 
8H, 4x C(CH2), 3.24 (m, 4H, 4x H-2), 2.22 (m, 4H, 4x H-3), 2.17, 
2.10, 2.09, 2.05, 2.04, 1.99 (s, 54H, 18 x COCH3), 13C NMR (CDCl3, 
125.76 MHz): δ (ppm) 170.7, 170.4, 169.8, 169.7, 159.5, 168.5 (6C, 
6 x CO), 144.9, (Cq-Tr), 123.6 (CH-Tr), 98.7 (C-1), 82.3 (C-1’), 
70.8, 70.4, 70.3, 69.9, 69.3, 69.2, 69.1, 68.7, 66.8, 66.1, 64.6, 64.5 
(73 C, skeleton carbons and OCH2), 62.8 (C-6), 62.1 (C-6’), 51.0 
(NCH2), 45.1 (Cq), 44.6 (C-2), 29.5 (C-3), 20.9, 20.7, 20.6 (COCH3). 
MALDI-TOF (positive ion): m/z calcd for C145H216N12NaO76S4: 
3492.22 [M+Na]+ Found: 3492.32. 
4.7.10. Compound 14 
Azide compound 2 (297 mg, 0.5 mmol) and alkyne 6 (30 mg, 0.1 
mmol) were reacted in DMF according to the general method A. 
The crude product was purified by flash chromatography (24:8:1 
CH2Cl2: MeOH:water) to give compound 14 (165 mg, 65%) as a 
colourless syrup. 
Compound 14 was was also prepared by deacetylation of 
compound 13 (75 mg, 0.02 mmol)) according to general method 
B to result in to result in compound 14 (43 mg, 84%). [α]24D 
+89.72 (c 0.27, MeOH); Rf 0.20 (24:8:1 methanol:toluene:water); 
1H NMR (DMSO, 500.76MHz): δ (ppm) 8.04 (s, 4H, 4x H-Tr), 5.21 
(s, 4H, 4x H-1’), 4.79 (s, 4H, 4x H-1), 4.53 (m, 8H, 4x NCH2), 4.48 
(m, 8H, 4xOCH2), 3.90- 3.20 (overlapping signals, 128H, skeleton 
hydrogens and OCH2), 3.12 (s, 4H, 4x H-2), 2.09 (m, 4H, 4x H-3a), 
1.96 (m, 4H, 4x H-3b), 13C NMR (DMSO, 125.76 MHz): δ (ppm) 
144.1 (Cq-Tr), 124.0 (CH-Tr), 98.4 (C-1), 86.4 (C-1’), 74.6, 74.4, 
71.7, 71.6, 69.8, 69.7, 69.6, 69.5, 68.7, 67.3, 65.7, 64.1, 61.9 
(skeleton carbons and OCH2), 61.1 (C-6’), 61.0 (C-6), 49.3 (NCH2), 
45.4 (C-2), 44.8 (Cq), 33.5 (C-3). MALDI-TOF (positive ion):  m/z 
calcd for C97H168N12NaO52S4 [(M+Na)+]: 2483.97. Found: 
2483.94. 
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• Four glycoclusters with terminal 1,2-thio-linked pseudomannobiosides were 
prepared. 
• Two glycoclusters were studied in lectin-binding assays with the BC2L-A 
lectin. 
• ITC, SPR, yeast agglutination test and analytical ultracentrifugation were 
applied. 
• The mannoclusters cross-link and aggregates BC2L-A of Burkholderia 
cenocepacia. 
